Table 6.
Best-fitting multiple linear regression analysis for factors associated with FGF21 in CHC patients (n=75)
| Variables | B | P-values | 95% CI for B |
|---|---|---|---|
| Age (years) | −0.081 | 0.491 | −1.3 to 0.561 |
| BMI (kg/m2) | 0.003 | 0.981 | −6.368 to 6.2 |
| Albumin (g/dL) | 0.273 | 0.025 | 3.26 to 45.9 |
| FBS | 0.05 | 0.8 | −0.786 to 0.648 |
| Insulin (uIU/mL) | 0.3 | 0.399 | −1.16 to 2.89 |
| HOMA-IR | −4.6 | 0.645 | 10.9 to 6 |
| Cholesterol (mg/dL) | 0.08 | 0.5 | −0.151 to 0.293 |
| TG (mg/dL) | −0.218 | 0.115 | −0.10 to 0.901 |
| LDL (mg/dL) | −0.250 | 0.08 | −0.87 to 0.052 |
| HDL (mg/dL) | 0.229 | 0.05 | 8.7 to 0.052 |
| Fibrosis (F1–F4) | −0.721 | 0.02 | −63.63 to 4.82 |
Abbreviations: BMI, body mass index; CHC, chronic hepatitis C; FBS, fasting blood sugar; FGF21, fibroblast growth factor 21; HDL, high-density lipoprotein; HOMA-IR, homeostasis model of insulin resistance; LDL, low-density lipoprotein; TG, triglyceride.